Dashboard
Arvinas, Inc.
ARVNNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jun 26Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jun 26Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jun 26Ownership changeSEC
Form 4 insider transaction filing.
- Jun 26Ownership changeSEC
Form 4 insider transaction filing.
- Jun 26Ownership changeSEC
Form 4 insider transaction filing on 2026-06-26.
- Jun 26Ownership changeSEC
Form 4 insider transaction filing
- Jun 25OtherSEC
8-K filed on submission of matters to security holder vote (item 5.07).
- Jun 24Ownership changeSEC
Form 4 insider ownership report filed.
- Jun 22LeadershipSEC
8-K item 5.02: disclosure of officer or director change.
- Jun 18Ownership changeSEC
SEC Form 4 insider ownership change filing.
- Jun 16OtherSEC
Arvinas filed 8-K (item 8.01) on other events.
- Jun 2Trial readoutClinicalTrials.gov
Pfizer-sponsored Phase 1 trial (NCT05930925) of ARV-471 in healthy adults completed
- Jun 2OtherSEC
Arvinas filed Form 8-K (items 7.01, 8.01, 9.01) on 2026-06-02.
- May 22Ownership changeSEC
SEC Form 4 insider ownership change filing
- May 13Ownership changeSEC
Form 4 insider transaction filing.
- May 13Ownership changeSEC
Form 4 insider ownership change filing on 2026-05-13.
- May 13Ownership changeSEC
SEC Form 4 insider transaction filing dated 2026-05-13.
- May 13Ownership changeSEC
Form 4 insider beneficial ownership filing.
- May 13Ownership changeSEC
Form 4 insider ownership change filing on 2026-05-13.
- May 12DealSEC
8-K (items 1.01/7.01/9.01) disclosing entry into material definitive agreement.
Not financial advice — research and opinion only. Disclosures